Last reviewed · How we verify
Cyclosporin A,mycophenolate mofetil,Methotrexate
This triple immunosuppressive combination inhibits T-cell activation and proliferation through calcineurin inhibition, inosine monophosphate dehydrogenase inhibition, and folate antagonism.
This triple immunosuppressive combination inhibits T-cell activation and proliferation through calcineurin inhibition, inosine monophosphate dehydrogenase inhibition, and folate antagonism. Used for Organ transplant rejection prevention, Autoimmune diseases (likely graft-versus-host disease or similar conditions).
At a glance
| Generic name | Cyclosporin A,mycophenolate mofetil,Methotrexate |
|---|---|
| Sponsor | Guangxi Medical University |
| Drug class | Immunosuppressive combination therapy |
| Target | Calcineurin, IMPDH, dihydrofolate reductase |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
Cyclosporin A blocks calcineurin-dependent T-cell activation by inhibiting IL-2 production. Mycophenolate mofetil selectively inhibits inosine monophosphate dehydrogenase, depleting guanosine nucleotides needed for lymphocyte proliferation. Methotrexate inhibits dihydrofolate reductase, further suppressing T and B cell proliferation. Together, these agents provide multi-target immunosuppression.
Approved indications
- Organ transplant rejection prevention
- Autoimmune diseases (likely graft-versus-host disease or similar conditions)
Common side effects
- Nephrotoxicity
- Hepatotoxicity
- Bone marrow suppression
- Infections
- Gastrointestinal disturbances
- Hypertension
Key clinical trials
- A Study to Evaluate Axatilimab Versus Best Available Therapy in Pediatric Participants With Chronic Graft-Versus-Host Disease After at Least 2 Prior Lines of Systemic Therapy (AGAVE-256) (PHASE2)
- Study on the Efficacy and Safety of the TmBU Conditioning Regimen in High-risk or Relapsed/Refractory Acute Leukemia (PHASE2)
- This Study is a Non-interventional Disease Registry of Adolescent and Adult Patients With Atopic Dermatitis Who Initiate or Switch Any Systemic Treatment
- Vorinostat for Graft vs Host Disease Prevention in Children, Adolescents and Young Adults Undergoing Allogeneic Blood and Marrow Transplantation (PHASE1, PHASE2)
- Targeted Dose Study of ATG in Haploidentical Hematopoietic Stem Cell Transplantation (PHASE3)
- Utilization of a Microdevice for Psoriasis and Atopic Dermatitis (PHASE4)
- GRAVITAS-119: Itacitinib in Combination With Calcineurin Inhibitor-Based Interventions for the Prophylaxis of Graft-Versus Host Disease (PHASE1)
- Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: